PLoS ONE, Год журнала: 2023, Номер 18(7), С. e0288350 - e0288350
Опубликована: Июль 14, 2023
Coronavirus disease of 2019 (COVID-19) is a global health problem. The impact chronic liver diseases on the course and outcome COVID-19 still subject research. aim this study was to show characteristics patients with diseases, establish risk factors for unfavourable outcome.
Язык: Английский
The Australian Journal of Anthropology, Год журнала: 2025, Номер unknown
Опубликована: Март 4, 2025
Abstract Drawing on 14 months of ethnographic research in Bangladesh, I analyse how the COVID‐19 pandemic intersected with global and local healthcare markets 2020 to shape public health governance affecting interests, needs, lives. In early phase, misuse administrative power corruption among bureaucrats, government representatives, political leaders became apparent Bangladesh. It fostered private catastrophes, exposing some fraudulence medical equipment provision treatment disease. Due state's denial, citizens were deprived low‐cost solutions (e.g. rapid antigen test kits) for infection detection. Engaging concept disaster capitalism, argue that elusive role state, politicised ground governance, medicine market combined sectors ultimately benefited corporations rather than urgent needs Bangladeshis.
Язык: Английский
Процитировано
0
BioMed Research International, Год журнала: 2023, Номер 2023(1)
Опубликована: Янв. 1, 2023
The world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia humans. virus was first reported Wuhan, China, early December 2019, and it quickly became global concern due to the pandemic. Challenges this regard have been compounded by emergence several variants such B.1.1.7, B.1.351, P1, B.1.617, which show increase transmission power resistance therapies vaccines. Ongoing researches are focused on developing manufacturing standard treatment strategies effective vaccines control Despite Pfizer/BioNTech Moderna approved U.S. Food Drug Administration (FDA) other phase 4 clinical trials, preventive measures mandatory COVID-19 In review, based latest findings, we will discuss different types drugs therapeutic options confirmed or vaccine candidates against SARS-CoV-2. We also detail challenges posed their effect interventions.
Язык: Английский
Процитировано
8
Frontiers in Medicine, Год журнала: 2022, Номер 9
Опубликована: Март 4, 2022
There are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly more progressed phase. This study aims to evaluate effect reducing length hospital stay in-hospital mortality among moderate severe hospitalized COVID-19 patients.A prospective, multicenter observational was conducted that included adult patients four major regions (Riyadh (Riyadh), Eastern (Dammam), Al-Qassem (Buraydah), Macca (Jeddah) Saudi Arabia. For primary outcome all-cause mortality, a Cox proportional hazard analysis performed. While association between use determined using adjusted generalized linear model. approved by Central Institutional Review Board The Ministry Health (MoH) with approval number IRB # 20-85-M.This 598 patients, whom 156 (26%) received favipiravir. Favipiravir treatment associated extended stays (14 vs. 10 median days, P = 0.034) higher rate (aHR 3.63; 95% CI 1.06-12.45) compared no regimen. Despite lack effectiveness, only diarrhea adverse effects (12 5%, 0.002), but it did not affect renal liver profiles patients.Favipiravir ineffective COVID-19.
Язык: Английский
Процитировано
12
Current Therapeutic Research, Год журнала: 2023, Номер 98, С. 100699 - 100699
Опубликована: Янв. 1, 2023
Herbal medicines have been extensively used to treat coronavirus disease 2019 (COVID-19). Garlic, known exert antiviral and anti-inflammatory effects, can be coadministered with standard treatments combat COVID-19.The aim of the study was evaluate efficacy safety profile Gallecina oral capsules (Samisaz Pharmaceutical Company, Mashhad, Iran), a fortified garlic extract, as adjunctive therapy improve clinical status symptoms in noncritically ill patients hospitalized for COVID-19.This triple-blind randomized, placebo-controlled trial conducted on COVID-19 nonintensive care wards Imam Hassan Hospital. Patients received remdesivir plus 90 mg capsule or placebo every 8 hours 5 days until discharge. The status, respiratory symptoms, laboratory parameters were recorded during period.Patients enrolled between April 24 July 18, 2021. Data from 72 group 69 analyzed. Oxygen saturation, C-reactive protein levels, distribution distress cough similar groups day Although body temperature significantly lower than that discharge (P = 0.04), it within normal range both groups. proportion requiring supplemental oxygen at least 1 reduced 3 4 < 0.05). Gastrointestinal complaints more prevalent but difference not statistically significant 0.12).There no effect primary outcome 6. Gallecina-treated who needed decreased discharge, there other days. possible beneficial effects requirements may warrant further investigation. (Curr Ther Res Clin Exp. 2023; 84:XXX-XXX). Clinical registration: IRCT20201111049347N1.
Язык: Английский
Процитировано
7
Frontiers in Public Health, Год журнала: 2023, Номер 11
Опубликована: Март 23, 2023
Three years since the first cases were identified and 2 an effective vaccine was developed, COVID-19 continues to claim lives impact people's health wellbeing, both socially economically. While world has been waiting for its leaders come together form a collective response end pandemic, we still have not seen multisectoral response, nor any whole-of-society approach. Like many other countries around globe, Türkiye caught unprepared by pandemic. This exacerbated unsuccessful management of pandemic authorities. The reasoning and/or scientific explanations enforcing or lifting public measures never shared with public. Throughout no epidemiological details released on deaths, than numbers these two measures. Civil society organizations, professional associations, in general kept out from policy formulation decision making. As result, community engagement properly put into practice. In this paper, analyzed Türkiye's through continuum cycle emergencies: prevention, preparedness, readiness, recovery.
Язык: Английский
Процитировано
7
Viruses, Год журнала: 2024, Номер 16(4), С. 651 - 651
Опубликована: Апрель 22, 2024
Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical trials, in Vero cells. Ratios reported unbound peak plasma concentrations, (Cmax)/EC50, were used to predict the potential vivo efficacy. The 20 with highest ratios retested human Calu-3 Caco-2 cells, their CC50 was determined an expanded panel cell lines. Many inactive Antivirals controlled trials had Cmax/EC50 ≥ 6.8 or EC50 nucleoside analogs dependent. This approach earlier availability more relevant cultures could reduced number unwarranted trials.
Язык: Английский
Процитировано
2
The American Journal of Emergency Medicine, Год журнала: 2024, Номер 85, С. 98 - 107
Опубликована: Сен. 4, 2024
Язык: Английский
Процитировано
2
Frontiers in Medicine, Год журнала: 2022, Номер 9
Опубликована: Сен. 15, 2022
Background Although several studies have assessed the safety, efficacy, and effectiveness of interventions in treating COVID-19, many them limitations that can an immense impact on their results. This study aims to assess potential systematic reviews (SRs) evaluate effect treatment COVID-19. Methods PubMed, Scopus, Web Sciences (WOS) databases were searched from inception January 1, 2022. All investigated effectiveness, outcome main intervention (Favipiravir, Remdesivir, Hydroxychloroquine, Ivermectin, Lopinavir/Ritonavir, or Tocilizumab) for COVID-19 patients reported included studies. We quality using Quality Assessment Tool (QAT) review articles. conducted a content analysis prepared narrative summary limitations. Results Forty-six this review. Ninety one percent scored as strong remaining (9%) moderate quality. Only 29.7% registered protocol. 26% mentioned funding statement. The categorized 10 domains: sample size, heterogeneity, follow-up, treatment, including studies, design, definitions, synthesis, quality, search. Conclusion Various been all Indeed, existence affect results, therefore, identifying these help researchers design better As result, stronger with more reliable results will be disseminated. Further research SRs is essential improve also, efficiency among scientists across world.
Язык: Английский
Процитировано
9
Biomedicines, Год журнала: 2022, Номер 10(11), С. 2815 - 2815
Опубликована: Ноя. 4, 2022
The vaccine weapon has resulted in being essential fighting the COVID-19 outbreak, but it is not fully preventing infection due to an alarming spreading of several identified variants concern. In fact, recent emergence pointed out how SARS-CoV-2 pandemic still represents a global health threat. Moreover, oral antivirals also develop resistance, supporting need find new targets as therapeutic tools. However, cocktail therapy useful reduce drug resistance and maximize vaccination efficacy. Natural products metal-drug-based treatments have shown interesting antiviral activity, representing valid contribution counter outbreak. This report summarizes available evidence which supports use approved drugs further focuses on significant clinical trials that investigated safety efficacy repurposing molecules different phenotypes. To date, there are many individuals vulnerable exhibiting severe symptoms, thus characterizing strategies for better management disease challenge.
Язык: Английский
Процитировано
9
Saudi Pharmaceutical Journal, Год журнала: 2023, Номер 31(4), С. 510 - 516
Опубликована: Фев. 15, 2023
We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard care (SC) in moderately severely ill COVID-19 patients from Saudi healthcare payer perspective.
Язык: Английский
Процитировано
5